OncoMatch/Clinical Trials/NCT06305832

Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer

Is NCT06305832 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Rezvilutamide and Androgen deprivation therapy (ADT) for prostate cancer.

Phase 2RecruitingThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNCT06305832Data as of May 2026

Treatment: Rezvilutamide · Androgen deprivation therapy (ADT) — To evaluate the efficacy and safety of rezvilutamide in combination with androgen deprivation therapy(ADT) and standard salvage radiation therapy(SRT) or SRT combination with ADT in prostate cancer patients with biochemical recurrence of prostate-specific antigen(PSA) persistence after radical prostatectomy(RP).

Check if I qualify

Extracted eligibility criteria

Cancer type

Prostate Cancer

Disease stage

Required: Stage PN0, PNX, PT3 (pathological)

Postoperative pathological stage pN0 or pNx; Postoperative pathological stage PT3/T4

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: endocrine therapy (goserrelin, levoprorelin, digarek, bicalutamide, abiraterone acetate, darotamine, apatamide, enzalutamide)

Previously received endocrine therapy for prostate cancer (including but not limited to goserrelin, levoprorelin, digarek, bicalutamide, abiraterone acetate, darotamine, apatamide, enzalutamide, etc.)

Cannot have received: pelvic radiotherapy

Previously received...pelvic radiotherapy

Lab requirements

Blood counts

Neutrophil count (ANC)≥1.5×10^9/L (no granulocyte colony-stimulating factor for 2 weeks prior to cycle 1, day 1); Platelet count (PLT)≥100×10^9/L (no transfusion within 2 weeks prior to day 1 of cycle 1); Hemoglobin (Hb) ≥90g/L

Kidney function

Serum creatinine (Cr)≤1.5×ULN or creatinine clearance > 50ml/min

Liver function

Total bilirubin (BIL)≤1.5×ULN; AST/SGOT or ALT/SGPT level ≤2.5×ULN

Cardiac function

Left ventricular ejection fraction (LVEF) ≥50%

Adequate hematological and organ function tests within 4 weeks prior to the first study treatment, as defined below: Neutrophil count (ANC)≥1.5×10^9/L (no granulocyte colony-stimulating factor for 2 weeks prior to cycle 1, day 1); Platelet count (PLT)≥100×10^9/L (no transfusion within 2 weeks prior to day 1 of cycle 1); Hemoglobin (Hb) ≥90g/L; Serum creatinine (Cr)≤1.5×ULN or creatinine clearance > 50ml/min; Total bilirubin (BIL)≤1.5×ULN; Aspartate aminotransferase (AST/SGOT) or alanine aminotransferase (ALT/SGPT) level ≤2.5×ULN; International Standardized ratio (INR) ≤1.5, prothrombin time (PT) and activated partial thromboplastin time (APTT) ≤1.5×ULN; Left ventricular ejection fraction (LVEF) ≥50%

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify